Bottneuro

Bottneuro operates at the intersection of neurotechnology, medical devices, digital therapeutics, and Alzheimer’s care. Its stated focus is differentiated from conventional drug-development approaches because it combines a custom, non-invasive stimulation device with EEG monitoring and patient-specific stimulation protocols. The company’s Miamind Neurostimulator is designed for early- and moderate-stage Alzheimer’s patients, while the NENI platform is described as the basis for developing stimulation protocols. This gives Bottneuro a potentially distinctive position between clinic-based neuromodulation systems and software-only digital therapeutics. The company’s differentiation is therefore best assessed through its technology claims and development stage rather than market share. Its 2022 financing of approximately $4.47 million in total disclosed funding is modest for a medical-device company entering clinical development, suggesting a focused early-stage profile rather than a scaled commercial operation. Three granted patents, including work related to electrode helmets and patient-specific electrostimulation, provide some defensibility. The main market-position risks are clinical validation, regulatory clearance, reimbursement, and the unresolved leadership transition.

Bottneuro’s trajectory shows progression from founding and early grant support into device development, clinical work, and initial commercialization activity. Founded in 2021, the company received a CHF 150,000 Venture Kick grant on Dec 17, 2021, followed by an undisclosed IMD Startup Competition grant on Dec 12, 2022. On Dec 15, 2022, it raised a CHF 4 million convertible note, equivalent to approximately $4.31 million, from Zühlke Ventures AG, Hemex, and DART Ventures. The financing appears to have supported advancement of its Miamind Neurostimulator and NENI stimulation platform. By Jan 7, 2024, Bottneuro had entered the clinical phase, and by Aug 7, 2024 it had launched a Priority Access Program after a successful study. Those milestones represent the company’s main development inflection points: moving from technology and patent formation to clinical testing and early market access. The available employee range is 11–50, but no time series is provided, so headcount growth cannot be quantified. Leadership activity in 2025 may signal an organizational transition, although current records conflict over whether Bekim Osmani or Thomas Hefti is CEO.